Further bolstering its ambitious vaccine program, Pfizer has teamed up with Cytos Biotechnology to develop, manufacture and commercialize vaccines for a defined number of human diseases. Cytos gains CHF 10 million up-front and up to CHF 140 in possible additional milestones. The company could also score research funding and royalties on any products that make it to market. The deal incorporates specific disease targets which are outside the scope of Cytos' own programs.
In a statement, Cytos exec Dr. Mark Dyer cheered the recent resurgance of the vaccine industry. "The vaccine market, including therapeutic vaccines, represents an increasingly attractive segment of the healthcare market. This collaboration with Pfizer further establishes Cytos Biotechnology's Immunodrugs as the vaccines of choice for top-tier pharmaceutical companies."
- take a look at the release
Note: The deal does not cover Cytos' current programs--NIC002 for nicotine addiction, CYT003-QbG10 for rhinitis and asthma, CAD106 for Alzheimer's disease, CYT004-MelQbG10 for melanoma and CYT006-AngQb for hypertension--as originally stated.